GILD
Gilead Sciences, Inc.
GILD has the edge over NVO overall, supported by lower modeled downside.
NVO
Novo Nordisk A/S
NVO offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
GILD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Strong | |
| Healthy |
GILD's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
GILD PE Valuation
GILD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 20x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
GILD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
GILD has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
GILD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.55 | — |
| Q3 2026 | -$3.15 | -149% |
| Q2 2026 | -$2.66 | -153% |
| Q1 2026 | $7.35 | +54% |
| Q4 2025 | $6.78 | +1684% |
| Q3 2025 | $6.46 | +7078% |
| Q2 2025 | $5.03 | +513% |
| Q1 2025 | $4.76 | +1222% |
| Q4 2024 | $0.38 | -92% |
GILD has swung to a loss: it lost $3.15 per share over the past year, after a profit the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over GILD on earnings quality, reporting a profit while its opponent remains loss making.
GILD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.3B | +6.8% |
| Q2 2026 | $7.8B | +10% |
| Q1 2026 | $7B | +4.4% |
| Q4 2025 | $7.9B | +4.7% |
| Q3 2025 | $7.8B | +3% |
| Q2 2025 | $7.1B | +1.8% |
| Q1 2025 | $6.7B | -0.3% |
| Q4 2024 | $7.6B | +6.4% |
GILD's revenue has grown year over year for six quarters in a row: $8.3B last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | -1.1 points |
| Q2 2026 | -133% | -168 points |
| Q1 2026 | 37% | +3.6 points |
| Q4 2025 | 25% | -7.4 points |
| Q3 2025 | 43% | +31 points |
| Q2 2025 | 35% | -3.1 points |
| Q1 2025 | 34% | +98 points |
| Q4 2024 | 32% | +9.7 points |
GILD has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over GILD on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
GILD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.8B | +21% |
| Q2 2026 | $3.4B | +377% |
| Q1 2026 | $2.4B | +47% |
| Q4 2025 | $3.1B | +10% |
| Q3 2025 | $4B | -5% |
| Q2 2025 | $720M | -40% |
| Q1 2025 | $1.7B | -22% |
| Q4 2024 | $2.8B | +45% |
GILD's free cash flow has been positive every quarter for seven years: $13.8B over the past year, up 50% from the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
GILD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +8M shares |
| 1 year | -0.2% | -3M shares |
| 3 years | -0.5% | -6M shares |
| 5 years | -0.9% | -11M shares |
| Available history | -2% | -26M shares |
GILD has 1.3B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $370M |
| Q2 2026 | $355M |
| Q1 2026 | $419M |
| Q4 2025 | $230M |
| Q3 2025 | $435M |
| Q2 2025 | $527M |
| Q1 2025 | $730M |
| Q4 2024 | $350M |
GILD spent $1.4B buying back its own shares over the past year, down 33% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
GILD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 1.4x | Healthy |
| Q4 2025 | 1.7x | Healthy |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 2.4x | Moderate |
| Q1 2025 | 2.0x | Healthy |
| Q4 2024 | 8.2x | High |
| Q3 2024 | 10.1x | High |
| Q2 2024 | 5.0x | High |
GILD's net debt is about 1.4 years of its operating earnings (EBITDA), down from 2.0 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over GILD on leverage, with a lower net debt burden relative to earnings.
GILD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.7 | Neutral |
| Stochastic | 83.3 | Overbought |
GILD's weekly RSI is 69 (neutral) and its Stochastic is 83 (overbought).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
GILD PE vs Healthcare Sector
| Metric | GILD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GILD has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GILD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $158.1 | 6.3% above |
| 20 week MA | $146.4 | 15% above |
| 50 week MA | $138.9 | 21% above |
| 100 week MA | $124.2 | 35% above |
| 200 week MA | $101.1 | 66% above |
GILD has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
GILD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66.0 | $57.1 | -13% |
| 2021 | $57.1 | $72.5 | +27% |
| 2022 | $72.5 | $84.8 | +17% |
| 2023 | $84.8 | $81.0 | -4.4% |
| 2024 | $81.0 | $94.1 | +16% |
| 2025 | $94.1 | $124.7 | +33% |
| 2026 YTD | $124.7 | $168.0 | +35% |
GILD has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.